Oncopeptides Revenue vs. Current Ratio
| ONCO Stock | SEK 1.54 0.03 1.99% |
For Oncopeptides profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncopeptides to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncopeptides AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncopeptides's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncopeptides AB over time as well as its relative position and ranking within its peers.
Oncopeptides |
Oncopeptides AB Current Ratio vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oncopeptides's current stock value. Our valuation model uses many indicators to compare Oncopeptides value to that of its competitors to determine the firm's financial worth. Oncopeptides AB is rated top company in revenue category among its peers. It also is considered to be number one stock in current ratio category among its peers . The ratio of Revenue to Current Ratio for Oncopeptides AB is about 14,842,534 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oncopeptides' earnings, one of the primary drivers of an investment's value.Oncopeptides Revenue vs. Competition
Oncopeptides AB is rated top company in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 16.47 Billion. Oncopeptides maintains roughly 118.3 Million in revenue contributing less than 1% to equities under Health Care industry.
Oncopeptides Current Ratio vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Oncopeptides |
| = | 118.3 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Oncopeptides |
| = | 7.97 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Oncopeptides Current Ratio Comparison
Oncopeptides is currently under evaluation in current ratio category among its peers.
Oncopeptides Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oncopeptides, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncopeptides will eventually generate negative long term returns. The profitability progress is the general direction of Oncopeptides' change in net profit over the period of time. It can combine multiple indicators of Oncopeptides, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Oncopeptides AB , a pharmaceutical company, develops drugs for the treatment of cancer. The company was founded in 2000 and is headquartered in Stockholm, Sweden. Oncopeptides is traded on Stockholm Stock Exchange in Sweden.
Oncopeptides Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oncopeptides. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncopeptides position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncopeptides' important profitability drivers and their relationship over time.
Use Oncopeptides in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncopeptides position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncopeptides will appreciate offsetting losses from the drop in the long position's value.Oncopeptides Pair Trading
Oncopeptides AB Pair Trading Analysis
The ability to find closely correlated positions to Oncopeptides could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncopeptides when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncopeptides - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncopeptides AB to buy it.
The correlation of Oncopeptides is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncopeptides moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncopeptides AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncopeptides can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Oncopeptides position
In addition to having Oncopeptides in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Food Products Thematic Idea Now
Food Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Food Products theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Food Products Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Oncopeptides Stock Analysis
When running Oncopeptides' price analysis, check to measure Oncopeptides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncopeptides is operating at the current time. Most of Oncopeptides' value examination focuses on studying past and present price action to predict the probability of Oncopeptides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncopeptides' price. Additionally, you may evaluate how the addition of Oncopeptides to your portfolios can decrease your overall portfolio volatility.